Clinical Trials Insight: 700034850
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2009
At a glance
- Drugs PSN 602 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors OSI Pharmaceuticals
- 24 Oct 2009 Results in a cohort of 38 patients presented at the 2009 Annual Meeting of the North American Association for the Study of Obesity (NAASO 2009).
- 12 May 2009 According to an OSI Pharmaceuticals media release, results of this trial will be presented at a scientific meeting in the second half of 2009. Results also reported in this media release.
- 12 May 2009 Status changed from recruiting to completed, according to an OSI Pharmaceuticals media release.